169 related articles for article (PubMed ID: 36935467)
1. Measuring Frailty Using Patient-Reported Outcomes (PRO) Data: A Feasibility Study in Patients with Multiple Myeloma.
Murugappan MN; King-Kallimanis BL; Bhatnagar V; Kanapuru B; Farley JF; Seifert RD; Stenehjem DD; Chen TY; Horodniceanu EG; Kluetz PG
Qual Life Res; 2023 Aug; 32(8):2281-2292. PubMed ID: 36935467
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported frailty phenotype (PRFP) vs. International Myeloma Working Group frailty index (IMWG FI) proxy: A comparison between two approaches to measuring frailty.
Murugappan MN; King-Kallimanis BL; Bhatnagar V; Kanapuru B; Farley JF; Seifert RD; Stenehjem DD; Chen TY; Horodniceanu EG; Kluetz PG
J Geriatr Oncol; 2024 Mar; 15(2):101681. PubMed ID: 38104480
[TBL] [Abstract][Full Text] [Related]
3. Association of IMWG frailty score with health-related quality of life profile of patients with relapsed refractory multiple myeloma in Italy and the UK: a GIMEMA, multicentre, cross-sectional study.
Efficace F; Gaidano G; Petrucci MT; Niscola P; Cottone F; Codeluppi K; Antonioli E; Tafuri A; Larocca A; Potenza L; Fozza C; Pastore D; Rigolin GM; Offidani M; Romano A; Kyriakou C; Cascavilla N; Gozzetti A; Derudas D; Vignetti M; Cavo M
Lancet Healthy Longev; 2022 Sep; 3(9):e628-e635. PubMed ID: 36102777
[TBL] [Abstract][Full Text] [Related]
4. A prospective observational study to assess clinical decision-making, prognosis, quality of life and satisfaction with care in patients with relapsed/refractory multiple myeloma: the CLARITY study protocol.
Efficace F; Boccadoro M; Palumbo A; Petrucci MT; Cottone F; Cannella L; Zamagni E; Niscola P; Kyriakou C; Caravita T; Offidani M; Mandelli F; Cavo M
Health Qual Life Outcomes; 2018 Jun; 16(1):127. PubMed ID: 29914509
[TBL] [Abstract][Full Text] [Related]
5. Comparison of EORTC QLQ-C30 and PRO-CTCAE™ Questionnaires on Six Symptom Items.
Taarnhøj GA; Kennedy FR; Absolom KL; Bæksted C; Vogelius IR; Johansen C; Velikova G; Pappot H
J Pain Symptom Manage; 2018 Sep; 56(3):421-429. PubMed ID: 29807157
[TBL] [Abstract][Full Text] [Related]
6. Reliability of an e-PRO Tool of EORTC QLQ-C30 for Measurement of Health-Related Quality of Life in Patients With Breast Cancer: Prospective Randomized Trial.
Wallwiener M; Matthies L; Simoes E; Keilmann L; Hartkopf AD; Sokolov AN; Walter CB; Sickenberger N; Wallwiener S; Feisst M; Gass P; Fasching PA; Lux MP; Wallwiener D; Taran FA; Rom J; Schneeweiss A; Graf J; Brucker SY
J Med Internet Res; 2017 Sep; 19(9):e322. PubMed ID: 28912116
[TBL] [Abstract][Full Text] [Related]
7. Psychometric properties of the EORTC QLQ-C30 in Uganda.
Naamala A; Eriksson LE; Orem J; Nalwadda GK; Kabir ZN; Wettergren L
Health Qual Life Outcomes; 2021 Apr; 19(1):131. PubMed ID: 33892718
[TBL] [Abstract][Full Text] [Related]
8. Standardising the Assessment of Patient-reported Outcome Measures in Localised Prostate Cancer. A Systematic Review.
Ratti MM; Gandaglia G; Alleva E; Leardini L; Sisca ES; Derevianko A; Furnari F; Mazzoleni Ferracini S; Beyer K; Moss C; Pellegrino F; Sorce G; Barletta F; Scuderi S; Omar MI; MacLennan S; Williamson PR; Zong J; MacLennan SJ; Mottet N; Cornford P; Aiyegbusi OL; Van Hemelrijck M; N'Dow J; Briganti A;
Eur Urol Oncol; 2022 Apr; 5(2):153-163. PubMed ID: 34785188
[TBL] [Abstract][Full Text] [Related]
9. Symptoms and quality of life in chronic pancreatitis assessed by structured interview and the EORTC QLQ-C30 and QLQ-PAN26.
Fitzsimmons D; Kahl S; Butturini G; van Wyk M; Bornman P; Bassi C; Malfertheiner P; George SL; Johnson CD
Am J Gastroenterol; 2005 Apr; 100(4):918-26. PubMed ID: 15784041
[TBL] [Abstract][Full Text] [Related]
10. Validation and reliability of the Dutch version of the EORTC QLQ-BLM30 module for assessing the health-related quality of life of patients with muscle invasive bladder cancer.
Ripping TM; Rammant E; Witjes JA; Aaronson NK; van Hemelrijck M; van Hoogstraten LMC; ; Kiemeney LA; Aben KKH
Health Qual Life Outcomes; 2022 Dec; 20(1):171. PubMed ID: 36581934
[TBL] [Abstract][Full Text] [Related]
11. International phase IV validation study of an EORTC quality of life questionnaire for testicular cancer patients: the EORTC QLQ-TC26.
Sztankay M; Aaronson NK; Arraras JI; Basso U; Bumbasirevic U; Efficace F; Giesinger JM; Johnson CD; van Leeuwen M; Oberguggenberger AS; Sosnowski R; Young T; Holzner B;
BMC Cancer; 2018 Nov; 18(1):1104. PubMed ID: 30419889
[TBL] [Abstract][Full Text] [Related]
12. How are patient-reported outcomes and symptoms being measured in adults with relapsed/refractory multiple myeloma? A systematic review.
LeBlanc MR; Hirschey R; Leak Bryant A; LeBlanc TW; Smith SK
Qual Life Res; 2020 Jun; 29(6):1419-1431. PubMed ID: 31848847
[TBL] [Abstract][Full Text] [Related]
13. Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.
Proskorovsky I; Lewis P; Williams CD; Jordan K; Kyriakou C; Ishak J; Davies FE
Health Qual Life Outcomes; 2014 Mar; 12():35. PubMed ID: 24618388
[TBL] [Abstract][Full Text] [Related]
14. Reliability and validity of Amharic version of EORTC QLQ-C30 and QLQ-BR23 modules for assessing health-related quality of life among breast cancer patients in Ethiopia.
Gadisa DA; Gebremariam ET; Ali GY
Health Qual Life Outcomes; 2019 Dec; 17(1):182. PubMed ID: 31830992
[TBL] [Abstract][Full Text] [Related]
15. Frailty Phenotypes and Relations With Surgical Outcomes: A Latent Class Analysis.
Sadiq F; Kronzer VL; Wildes TS; McKinnon SL; Sharma A; Helsten DL; Scheier LM; Avidan MS; Ben Abdallah A
Anesth Analg; 2018 Oct; 127(4):1017-1027. PubMed ID: 30113393
[TBL] [Abstract][Full Text] [Related]
16. International field testing of the psychometric properties of an EORTC quality of life module for oral health: the EORTC QLQ-OH15.
Hjermstad MJ; Bergenmar M; Bjordal K; Fisher SE; Hofmeister D; Montel S; Nicolatou-Galitis O; Pinto M; Raber-Durlacher J; Singer S; Tomaszewska IM; Tomaszewski KA; Verdonck-de Leeuw I; Yarom N; Winstanley JB; Herlofson BB;
Support Care Cancer; 2016 Sep; 24(9):3915-24. PubMed ID: 27113466
[TBL] [Abstract][Full Text] [Related]
17. Psychometric validation of the Moroccan version of the EORTC QLQ-C30 in colorectal Cancer patients: cross-sectional study and systematic literature review.
El Alami Y; Essangri H; Majbar MA; Boutayeb S; Benamr S; El Malki HO; Souadka A
BMC Cancer; 2021 Jan; 21(1):99. PubMed ID: 33499819
[TBL] [Abstract][Full Text] [Related]
18. Use of the European Organisation for Research and Treatment of Cancer multiple myeloma module (EORTC QLQ-MY20): a review of the literature 25 years after development.
Forde K; Cocks K; Wells JR; McMillan I; Kyriakou C;
Blood Cancer J; 2023 May; 13(1):79. PubMed ID: 37193682
[TBL] [Abstract][Full Text] [Related]
19. The validity of EORTC QLQ-C30 fatigue scale in advanced cancer patients and cancer survivors.
Knobel H; Loge JH; Brenne E; Fayers P; Hjermstad MJ; Kaasa S
Palliat Med; 2003 Dec; 17(8):664-72. PubMed ID: 14694917
[TBL] [Abstract][Full Text] [Related]
20. Development of a Fried Frailty Phenotype Questionnaire for Use in Screening Community-Dwelling Older Adults.
Chen S; Chen T; Kishimoto H; Susaki Y; Kumagai S
J Am Med Dir Assoc; 2020 Feb; 21(2):272-276.e1. PubMed ID: 31522878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
